SGMO: Sangamo Therapeutics Inc. Stocks News on October 26, 2025

SGMO

MT Newswires

a month ago

Sector Update: Health Care Stocks Fall Late Afternoon

SGMO

MT Newswires

a month ago

Sangamo Therapeutics CFO Prathyusha Duraibabu to Step Down

SGMO

MT Newswires

4 months ago

Sangamo Therapeutics Says Phase 1/2 Fabry Disease Study Showed Favorable Safety Profile; Shares Up Pre-Bell

Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease

SGMO

Business Wire

4 months ago

Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease

SGMO

GuruFocus.com

5 months ago

Sangamo Therapeutics Inc (SGMO) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ...

SGMO

Thomson Reuters StreetEvents

5 months ago

Q1 2025 Sangamo Therapeutics Inc Earnings Call

SGMO

GuruFocus.com

5 months ago

Sangamo Therapeutics Inc (SGMO) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ...

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results

SGMO

Business Wire

5 months ago

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results

Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering

SGMO

Business Wire

5 months ago

Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering

SGMO

Zacks

5 months ago

Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates

SGMO

Associated Press Finance

5 months ago

Sangamo: Q1 Earnings Snapshot

Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day

SGMO

Business Wire

5 months ago

Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day

Sangamo Therapeutics Announces First Quarter 2025 Earnings Call

SGMO

Business Wire

6 months ago

Sangamo Therapeutics Announces First Quarter 2025 Earnings Call

Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease

SGMO

Business Wire

6 months ago

Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease

SGMO

Zacks

6 months ago

Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

SGMO

Business Wire

6 months ago

Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

SGMO

MT Newswires

7 months ago

Sangamo Signs Capsid License Deal With Eli Lilly; Shares Rise After Hours

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System

SGMO

Business Wire

7 months ago

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System

SGMO

MT Newswires

7 months ago

Truist Removes Price Target From Sangamo Therapeutics, Keeps Buy Rating; Price Target Had Been $5

SGMO

Thomson Reuters StreetEvents

7 months ago

Q4 2024 Sangamo Therapeutics Inc Earnings Call

SGMO

GuruFocus.com

7 months ago

Sangamo Therapeutics Inc (SGMO) Q4 2024 Earnings Call Highlights: Strategic Advances and ...

SGMO

Zacks

7 months ago

Sangamo Therapeutics (SGMO) Reports Q4 Loss, Misses Revenue Estimates

SGMO

Associated Press Finance

7 months ago

Sangamo: Q4 Earnings Snapshot

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

SGMO

Business Wire

7 months ago

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference

SGMO

Business Wire

8 months ago

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference

SGMO

Simply Wall St.

8 months ago

Sangamo Therapeutics (NASDAQ:SGMO shareholders incur further losses as stock declines 15% this week, taking five-year losses to 89%

SGMO

Business Wire

9 months ago

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile

SGMO

Insider Monkey

10 months ago

Sangamo Therapeutics Inc. (SGMO): This Small-Cap Stock Is Poised To Outperform in 2025

SGMO

Zacks

10 months ago

Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More

Sangamo Therapeutics Stock Plummets 56% After Pfizer Ends Hemophilia Treatment Partnership

SGMO

Barrons.com

10 months ago

Sangamo Therapeutics Stock Plummets 56% After Pfizer Ends Hemophilia Treatment Partnership

SGMO

MT Newswires

10 months ago

Top Midday Decliners

Sangamo Therapeutics Stock Slumps After Pfizer Terminates Hemophilia A Gene Therapy Partnership

SGMO

MT Newswires

10 months ago

Sangamo Therapeutics Stock Slumps After Pfizer Terminates Hemophilia A Gene Therapy Partnership

SGMO

MT Newswires

10 months ago

Jefferies Cuts Price Target on Sangamo Therapeutics to $3 From $7, Keeps Buy Rating; Shares Fall

SGMO

MT Newswires

10 months ago

Pfizer Exit Sends Sangamo Plummeting 50%, Casting Doubt on Hemophilia Gene Therapy's Future

Sangamo Therapeutics Stock Crashes as Pfizer Ends Hemophilia Drug Pact

SGMO

Investopedia

10 months ago

Sangamo Therapeutics Stock Crashes as Pfizer Ends Hemophilia Drug Pact

SGMO

Insider Monkey

10 months ago

SGMO Pre-Market Shares Drop 40% Over Pfizer (PFE) Deal Collapse

Sangamo stock plummets 50% after Pfizer ends gene therapy deal

SGMO

Yahoo Finance Video

10 months ago

Sangamo stock plummets 50% after Pfizer ends gene therapy deal

Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact

SGMO

Benzinga

10 months ago

Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact

SGMO

MT Newswires

10 months ago

Sangamo's Cash on Balance Sheet Seen as 'Overhang' as Pfizer Pulls Out of Hemophilia A Therapy Study, Truist Says

SGMO

MT Newswires

10 months ago

Sector Update: Health Care

Sangamo’s stock sinks 50% as Pfizer halts haemophilia A gene therapy partnership

SGMO

Pharmaceutical Technology

10 months ago

Sangamo’s stock sinks 50% as Pfizer halts haemophilia A gene therapy partnership

SGMO

Investing.com

10 months ago

Sangamo stock crashes 50% after Pfizer terminates HemoA gene therapy deal

SGMO

Zacks

10 months ago

SGMO Stock Crashes as Pfizer Ends Deal for Hemophilia Candidate

SGMO

MT Newswires

10 months ago

Wells Fargo Adjusts Price Target on Sangamo Therapeutics to $2 From $3, Keeps Equalweight Rating

Astellas and Sangamo sign capsid deal for neurological diseases

SGMO

Pharmaceutical Technology

10 months ago

Astellas and Sangamo sign capsid deal for neurological diseases

SGMO

MT Newswires

10 months ago

Update: Sangamo Grants Capsid License to Astellas for Neurological Disease Targets; Shares Up Pre-Bell

SGMO

MT Newswires

10 months ago

Sangamo Grants Capsid License to Astellas for Neurological Disease Targets

Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases

SGMO

Business Wire

10 months ago

Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases

Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases

SGMO

PR Newswire

10 months ago

Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases

SGMO

MT Newswires

10 months ago

Truist Upgrades Sangamo Therapeutics to Buy From Hold, Reinstates Price Target at $7

Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain

SGMO

Business Wire

a year ago

Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain

Sangamo Therapeutics Third Quarter 2024 Earnings: Beats Expectations

SGMO

Simply Wall St.

a year ago

Sangamo Therapeutics Third Quarter 2024 Earnings: Beats Expectations

SGMO

Thomson Reuters StreetEvents

a year ago

Q3 2024 Sangamo Therapeutics Inc Earnings Call

SGMO

GuruFocus.com

a year ago

Sangamo Therapeutics Inc (SGMO) Q3 2024 Earnings Call Highlights: Strategic Advances and ...

SGMO

Zacks

a year ago

Sangamo Therapeutics (SGMO) Tops Q3 Earnings and Revenue Estimates

SGMO

Associated Press Finance

a year ago

Sangamo: Q3 Earnings Snapshot

Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results

SGMO

Business Wire

a year ago

Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results

Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast

SGMO

Business Wire

a year ago

Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast

SGMO

Simply Wall St.

a year ago

individual investors who own 55% along with institutions invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) saw increase in their holdings value last week

Merck acquires cancer drug startup; Elevidys ex-US sales rise

SGMO

BioPharma Dive

a year ago

Merck acquires cancer drug startup; Elevidys ex-US sales rise

SGMO

MT Newswires

a year ago

Sangamo Therapeutics Shares Surge After US FDA Clears Potential Fabry Disease Treatment for Expedited Review

Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025

SGMO

Business Wire

a year ago

Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025

SGMO

Simply Wall St.

a year ago

Investors in Sangamo Therapeutics (NASDAQ:SGMO) from three years ago are still down 90%, even after 13% gain this past week

SGMO

Simply Wall St.

a year ago

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Just Reported And Analysts Have Been Lifting Their Price Targets

SGMO

Thomson Reuters StreetEvents

a year ago

Q2 2024 Sangamo Therapeutics Inc Earnings Call

Genentech and Sangamo to develop neurodegenerative disease therapies

SGMO

Pharmaceutical Technology

a year ago

Genentech and Sangamo to develop neurodegenerative disease therapies

SGMO

Zacks

a year ago

Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates

SGMO

Associated Press Finance

a year ago

Sangamo: Q2 Earnings Snapshot

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results

SGMO

Business Wire

a year ago

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results

Roche licenses Sangamo’s technology for another shot at Alzheimer’s drugs

SGMO

BioPharma Dive

a year ago

Roche licenses Sangamo’s technology for another shot at Alzheimer’s drugs

Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases

SGMO

Business Wire

a year ago

Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases

Sangamo Therapeutics Announces Second Quarter 2024 Conference Call and Webcast

SGMO

Business Wire

a year ago

Sangamo Therapeutics Announces Second Quarter 2024 Conference Call and Webcast

Sangamo Therapeutics Reports on Pfizer’s Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate

SGMO

Business Wire

a year ago

Sangamo Therapeutics Reports on Pfizer’s Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate

Sarepta Therapeutics (SRPT) Soars 30.1%: Is Further Upside Left in the Stock?

SGMO

Zacks

a year ago

Sarepta Therapeutics (SRPT) Soars 30.1%: Is Further Upside Left in the Stock?

SGMO

Simply Wall St.

a year ago

We Think Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Compensation Package Needs To Be Put Under A Microscope

SGMO

Simply Wall St.

a year ago

US$3.50 - That's What Analysts Think Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Is Worth After These Results

SGMO

Insider Monkey

a year ago

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2024 Earnings Call Transcript

Sangamo Therapeutics First Quarter 2024 Earnings: US$0.27 loss per share (vs US$0.13 profit in 1Q 2023)

SGMO

Simply Wall St.

a year ago

Sangamo Therapeutics First Quarter 2024 Earnings: US$0.27 loss per share (vs US$0.13 profit in 1Q 2023)

SGMO

GuruFocus.com

a year ago

Sangamo Therapeutics Reports Q1 2024 Results: A Deep Dive into Financials and Strategic Highlights

SGMO

Zacks

a year ago

Sangamo Therapeutics (SGMO) Reports Q1 Loss, Lags Revenue Estimates

SGMO

Associated Press Finance

a year ago

Sangamo: Q1 Earnings Snapshot

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results

SGMO

Business Wire

a year ago

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results

Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing

SGMO

Business Wire

a year ago

Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing

Cardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates

SGMO

Zacks

a year ago

Cardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates

Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast

SGMO

Business Wire

a year ago

Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast

Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

SGMO

Business Wire

2 years ago

Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

SGMO

Simply Wall St.

2 years ago

What You Need To Know About The Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Analyst Downgrade Today

Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering

SGMO

Business Wire

2 years ago

Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering

Sangamo Therapeutics Full Year 2023 Earnings: Misses Expectations

SGMO

Simply Wall St.

2 years ago

Sangamo Therapeutics Full Year 2023 Earnings: Misses Expectations

SGMO

Thomson Reuters StreetEvents

2 years ago

Q4 2023 Sangamo Therapeutics Inc Earnings Call

SGMO

Associated Press Finance

2 years ago

Sangamo: Q4 Earnings Snapshot

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

SGMO

Business Wire

2 years ago

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs

SGMO

Business Wire

2 years ago

Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast

SGMO

Business Wire

2 years ago

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast

Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease

SGMO

Business Wire

2 years ago

Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease

SGMO

Simply Wall St.

2 years ago

With 55% ownership of the shares, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is heavily dominated by institutional owners

SGMO

Business Wire

2 years ago

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile

Seanergy Maritime Achieves Key Partnership with European Union Funding and Major Industry Stakeholders Under SAFeCRAFT to Revolutionize Maritime Propulsion for Existing Vessels

SGMO

GlobeNewswire

2 years ago

Seanergy Maritime Achieves Key Partnership with European Union Funding and Major Industry Stakeholders Under SAFeCRAFT to Revolutionize Maritime Propulsion for Existing Vessels

GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SGMO

GlobeNewswire

2 years ago

Latest Sangamo Therapeutics Inc. (SGMO) News on October 26, 2025

Share on Social Networks: